{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T11:30:18Z","timestamp":1763811018616,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03325-7","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T07:58:04Z","timestamp":1676793484000},"page":"505-510","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["De-escalation treatment with pasireotide for acromegaly: a long-term experience"],"prefix":"10.1007","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5756-2045","authenticated-orcid":false,"given":"Antonella","family":"Giampietro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-3206","authenticated-orcid":false,"given":"Sara","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9241-2392","authenticated-orcid":false,"given":"Sabrina","family":"Chiloiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Pontecorvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"De Marinis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"issue":"6","key":"3325_CR1","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1210\/jc.2009-2272","volume":"95","author":"S Petersenn","year":"2010","unstructured":"S. Petersenn, J. Schopohl, A. Barkan, P. Mohideen, A. Colao, R. Abs, A. Buchelt, Y.-Y. Ho, K. Hu, A.J. Farrall, S. Melmed, B.M.K. Biller, Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J. Clin. Endocrinol. Metab. 95(6), 2781\u20132789 (2010). https:\/\/doi.org\/10.1210\/jc.2009-2272","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3325_CR2","doi-asserted-by":"publisher","unstructured":"A. Colao, M.D. Bronstein, T. Brue, L. de Marinis, M. Fleseriu, M. Guitelman, G. Raverot, I. Shimon, J. Fleck, P. Gupta, A.M. Pedroncelli, M.R. Gadelha, Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur. J. Endocrinol. 182(6), 583 (2020). https:\/\/doi.org\/10.1530\/EJE-19-0762","DOI":"10.1530\/EJE-19-0762"},{"issue":"2","key":"3325_CR3","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12020-021-02782-2","volume":"74","author":"A Akirov","year":"2021","unstructured":"A. Akirov, A. Gorshtein, I. Dotan, N.S. Khazen, Y. Pauker, M. Gershinsky, I. Shimon, Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine 74(2), 396\u2013403 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02782-2","journal-title":"Endocrine"},{"key":"3325_CR4","doi-asserted-by":"publisher","unstructured":"S. Chiloiro, A. Giampietro, F. Mirra, F. Donfrancesco, T. Tartaglione, P.P. Mattogno, F. Angelini, L. Liverana, M. Gessi, A. Carmelo, G. Rindi, A. Giustina, M. Fleseriu, A. Pontecorvi, L. de Marinis, A. Bianchi, Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur. J. Endocrinol. 184(2), 217\u2013229 (2021). https:\/\/doi.org\/10.1530\/EJE-20-0767","DOI":"10.1530\/EJE-20-0767"},{"issue":"1","key":"3325_CR5","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"G. Raverot, P. Burman, A. McCormack, A. Heaney, S. Petersenn, V. Popovic, J. Trouillas, O.M. Dekkers, European Society of Endocrinology clinical practice guidelines for the management of aggressive pituitary tumours and carcinomas. Eur. J. Endocrinol. 178(1), G1\u2013G24 (2018). https:\/\/doi.org\/10.1530\/EJE-17-0796","journal-title":"Eur. J. Endocrinol."},{"issue":"9","key":"3325_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"S. Melmed, M.D. Bronstein, P. Chanson, A. Klibanski, F.F. Casanueva, J.A.H. Wass, C.J. Strasburger, A. Luger, D.R. Clemmons, A. Giustina, A Consensus Statement on acromegaly therapeutic outcomes. Nat. Rev. Endocrinol. 14(9), 552\u2013561 (2018). https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"3325_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"A. Giustina, G. Barkhoudarian, A. Beckers, A. Ben-Shlomo, N. Biermasz, B. Biller, C. Boguszewski, M. Bolanowski, J. Bollerslev, V. Bonert, M.D. Bronstein, M. Buchfelder, F. Casanueva, P. Chanson, D. Clemmons, M. Fleseriu, A.M. Formenti, P. Freda, M. Gadelha, E. Geer, M. Gurnell, A.P. Heaney, K.K.Y. Ho, A.G. Ioachimescu, S. Lamberts, E. Laws, M. Losa, P. Maffei, A. Mamelak, M. Mercado, M. Molitch, P. Mortini, A.M. Pereira, S. Petersenn, K. Post, M. Puig-Domingo, R. Salvatori, S.L. Samson, I. Shimon, C. Strasburger, B. Swearingen, P. Trainer, M.L. Vance, J. Wass, M.E. Wierman, K.C.J. Yuen, M.C. Zatelli, S. Melmed, Multidisciplinary management of acromegaly: a consensus. Rev. Endocr. Metab. Disord. 21(4), 667\u2013678 (2020). https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"6","key":"3325_CR8","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"E.C. Coopmans, A. Muhammad, A.J. van der Lely, J.A.M.J.L. Janssen, S.J.C.M.M. Neggers, How to position Pasireotide LAR treatment in acromegaly. J. Clin. Endocrinol. Metab. 104(6), 1978\u20131988 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01979","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3325_CR9","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1210\/jc.2018-01524","volume":"104","author":"A Muhammad","year":"2019","unstructured":"A. Muhammad, E.C. Coopmans, F. Gatto, S.E. Franck, J.A.M.J.L. Janssen, A.J. van der Lely, L.J. Hofland, S.J.C.M.M. Neggers, Pasireotide responsiveness in acromegaly is mainly driven by somatostatin receptor subtype 2 expression. J. Clin. Endocrinol. Metab. 104(3), 915\u2013924 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01524","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"3325_CR10","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"F. Gatto, R.A. Feelders, S.E. Franck, P.M. van Koetsveld, F. Dogan, J.M. Kros, S.J.C.M.M. Neggers, A.J. van der Lely, S.W.J. Lamberts, D. Ferone, L.J. Hofland, In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J. Clin. Endocrinol. Metab. 102(6), 2009\u20132018 (2017). https:\/\/doi.org\/10.1210\/jc.2017-00135","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3325_CR11","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","volume":"25","author":"M Chalabi","year":"2014","unstructured":"M. Chalabi, C. Duluc, P. Caron, D. Vezzosi, J. Guillermet-Guibert, S. Pyronnet, C. Bousquet, Somatostatin analogs: does pharmacology impact antitumor efficacy? Trends Endocrinol. Metab. 25(3), 115\u2013127 (2014). https:\/\/doi.org\/10.1016\/j.tem.2013.11.003","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"3325_CR12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Bana\u015b","year":"2022","unstructured":"M. Stelmachowska-Bana\u015b, I. Czajka-Oraniec, A. Tomasik, W. Zgliczy\u0144ski, Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25(1), 180\u2013190 (2022). https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"issue":"2","key":"3325_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s12020-022-03158-w","volume":"78","author":"S Chiloiro","year":"2022","unstructured":"S. Chiloiro, D. Costa, R. Lauretta, V. Mercuri, E. Sbardella, I. Samperi, M. Appetecchia, A. Bianchi, A. Giampietro, P. Gargiulo, A.M. Isidori, M. Poggi, A. Pontecorvi, De, L. Marinis, Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine 78(2), 343\u2013353 (2022). https:\/\/doi.org\/10.1007\/s12020-022-03158-w","journal-title":"Endocrine"},{"issue":"11","key":"3325_CR14","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1038\/modpathol.3800954","volume":"20","author":"M Volante","year":"2007","unstructured":"M. Volante, M.P. Brizzi, A. Faggiano, S. La Rosa, I. Rapa, A. Ferrero, G. Mansueto, L. Righi, S. Garancini, C. Capella, G. De Rosa, L. Dogliotti, A. Colao, M. Papotti, Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod. Pathol. 20(11), 1172\u20131182 (2007). https:\/\/doi.org\/10.1038\/modpathol.3800954","journal-title":"Mod. Pathol."},{"issue":"1","key":"3325_CR15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.14310\/horm.2002.1722","volume":"16","author":"I Shimon","year":"2017","unstructured":"I. Shimon, W. Saeger, L.E. Wildemberg, M.R. Gadelha, Somatotropinomas inadequately controlled with octreotide may over-respond to pasireotide: the importance of dose adjustment to achieve long-term biochemical control. Hormones (Athens) 16(1), 84\u201391 (2017). https:\/\/doi.org\/10.14310\/horm.2002.1722","journal-title":"Hormones (Athens)"},{"key":"3325_CR16","doi-asserted-by":"publisher","unstructured":"S. Chiloiro, A. Giampietro, F. Visconti, L. Rossi, F. Donfrancesco, C.M. Fleseriu, F. Mirra, A. Pontecorvi, A. Giustina, M. Fleseriu, L. de Marinis, A. Bianchi, Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine 73, 658\u2013666 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02711-3","DOI":"10.1007\/s12020-021-02711-3"},{"issue":"7","key":"3325_CR17","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","volume":"27","author":"S Frara","year":"2016","unstructured":"S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27(7), 470\u2013483 (2016). https:\/\/doi.org\/10.1016\/j.tem.2016.04.014","journal-title":"Trends Endocrinol. Metab."},{"key":"3325_CR18","doi-asserted-by":"publisher","unstructured":"A. Giustina, A. Barkan, A. Beckers, N. Biermasz, B.M.K. Biller, C. Boguszewski, M. Bolanowski, V. Bonert, M.D. Bronstein, F.F. Casanueva, D. Clemmons, A. Colao, D. Ferone, M. Fleseriu, S. Frara, M.R. Gadelha, E. Ghigo, M. Gurnell, A.P. Heaney, K. Ho, A. Ioachimescu, L. Katznelson, F. Kelestimur, J. Kopchick, M. Krsek, S. Lamberts, M. Losa, A. Luger, P. Maffei, M. Marazuela, G. Mazziotti, M. Mercado, P. Mortini, S. Neggers, A.M. Pereira, S. Petersenn, M. Puig-Domingo, R. Salvatori, I. Shimon, C. Strasburger, S. Tsagarakis, A.J. van der Lely, J. Wass, M.C. Zatelli, S. Melmed, A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J. Clin. Endocrinol. Metab. 105(4), dgz096 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz096","DOI":"10.1210\/clinem\/dgz096"},{"issue":"9","key":"3325_CR19","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1210\/jc.2016-1257","volume":"101","author":"P Chanson","year":"2016","unstructured":"P. Chanson, A. Arnoux, M. Mavromati, S. Brailly-Tabard, C. Massart, J. Young, M.L. Piketty, J.C. Souberbielle; VARIETE Investigators, Reference values for IGF-I serum concentrations: comparison of six immunoassays. J. Clin. Endocrinol. Metab. 101(9), 3450\u20133458 (2016). https:\/\/doi.org\/10.1210\/jc.2016-1257","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"3325_CR20","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ecl.2020.05.010","volume":"49","author":"S Frara","year":"2020","unstructured":"S. Frara, G. Rodriguez-Carnero, A.M. Formenti, M.A. Martinez-Olmos, A. Giustina, F.F. Casanueva, Pituitary tumors centers of excellence. Endocrinol. Metab. Clin. North Am. 49(3), 553\u2013564 (2020). https:\/\/doi.org\/10.1016\/j.ecl.2020.05.010","journal-title":"Endocrinol. Metab. Clin. North Am."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03325-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T07:21:29Z","timestamp":1684567289000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03325-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,18]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["3325"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03325-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2023,2,18]]},"assertion":[{"value":"2 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A.G., S.M., S.C., L.D.M. and A.B. have served as investigator for clinical trials funded by Novartis, Pfizer, Ipsen and Crinetics. S.C. and A.B. received grants from Pfizer. S.C. won the 2022 Arrigo Recordati research grant. All the fees and honoraria are paid to their institution. They are members of Advisor Board for Novartis, Pfizer, Recordati.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. The approval was granted by the Ethics Committee of Universit\u00e0 Cattolica del Sacro Cuore.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}